Table 2.
RBC and PLT transfusion burden and transfusion independence of patients undergoing HSCT according to the 3 study periods. Cumulative incidence of competing events, Gray test and Kruskal–Wallis test were used to compare the groups.
| 2009–2012 | 2013–2016 | 2017–2020 | p | |
|---|---|---|---|---|
| MRD | ||||
| Patients, n (%) | 120 (34) | 131 (36) | 107 (30) | |
| RCB transfusion independence | 0.06 | |||
| Days, median (range) | 10.5 (0–153) | 11.5 (0–310) | 17.5 (0–190) | |
| CuI at 100 days, % (95% CI) | 85 (78–91) | 85 (78–90) | 79 (70–86) | |
| PLT transfusion independence | 0.0001 | |||
| Days, median (range) | 11 (0–80) | 11 (0–110) | 19 (7–155) | |
| CuI at 100 days, % (95% CI) | 94 (87–97) | 94 (88–97) | 87 (79–92) | |
| RBC units at day +30, median (range) | 2 (0–21) | 3 (0–24) | 4 (0–38) | <0.0001 |
| RBC units, day 31–90 *, median (range) | 4 (2–53) | 6 (2–49) | 4 (1–30) | 0.5 |
| PLT units at day +30, median (range) | 3 (0–55) | 3 (0–70) | 5 (1–39) | 0.002 |
| PLT units, day 31–90 *, median (range) | 19 (1–99) | 14 (1–83) | 14 (1–85) | 0.12 |
| MUD | ||||
| Patients, n (%) | 14 (11) | 26 (19) | 94 (70) | |
| RCB transfusion independence | 0.61 | |||
| Days, median (range) | 25.5 (0–149) | 12 (0–100) | 26 (0–260) | |
| CuI at 100 days, % (95% CI) | 78 (40–93) | 80 (57–92) | 84 (75–90) | |
| PLT transfusion independence | 0.23 | |||
| Days, median (range) | 18 (6–22) | 22 (6–173) | 25 (3–210) | |
| CuI at 100 days, % (95% CI) | 85 (53–96) | 88 (68–96) | 90 (81–95) | |
| RBC units at day +30, median (range) | 5 (0–23) | 4 (0–21) | 4 (0–23) | 0.31 |
| RBC units, day 31–90 *, median (range) | 4 (2–12) | 5 (2–16) | 5 (1–85) | 0.8 |
| PLT units at day +30, median (range) | 10 (5–70) | 6 (1–48) | 7 (2–69) | 0.12 |
| PLT units, day 31–90 *, median (range) | 6 (1–23) | 2 (1–57) | 10 (2–49) | 0.07 |
| Haploidentical | ||||
| Patients, n (%) | 7 (5) | 49 (35) | 84 (60) | |
| RCB transfusion independence | 0.097 | |||
| Days, median (range) | 29.5 (10–48) | 25.5 (0–290) | 21 (0–255) | |
| CuI at 100 days, % (95% CI) | 28 (4–61) | 67 (51–78) | 74 (63–82) | |
| PLT transfusion independence | 0.12 | |||
| Days, median (range) | 23 (6–35) | 26 (22–72) | 28 (0–169) | |
| CuI at 100 days, % (95% CI) | 28 (4–61) | 67 (52–78) | 84 (73–90) | |
| RBC units at day +30, median (range) | 10 (5–18) | 6 (0–23) | 5 (0–18) | 0.08 |
| RBC units, day 31–90 *, median (range) | 2 (2–2) | 6 (2–12) | 6 (0–79) | 0.15 |
| PLT units at day +30, median (range) | 14 (10–38) | 11 (3–30) | 8 (2–28) | 0.13 |
| PLT units, day 31–90 *, median (range) | 11 (1–12) | 10 (2–41) | 10 (2–124) | 0.3 |
| UCBT | ||||
| Patients, n (%) | 116 (52) | 91 (41) | 16 (7) | |
| RCB transfusion independence | 0.17 | |||
| Days, median (range) | 33 (0–240) | 28 (0–183) | 33 (0–200) | |
| CuI at 100 days, % (95% CI) | 63 (53–71) | 54 (44–64) | 73 (40–90) | |
| Platelet transfusion independence | 0.001 | |||
| Days, median (range) | 35 (0–175) | 34 (0–180) | 34 (0–60) | |
| CuI at 100 days, % (95% CI) | 73 (64–81) | 67 (56–75) | 93 (61–99) | |
| RBC units at day +30, median (range) | 6 (0–18) | 6 (0–39) | 5 (3–12) | 0.4 |
| RBC units, day 31–90 *, median (range) | 6 (3–29) | 6 (3–53) | 6 (3–12) | 0.8 |
| PLT units at day +30, median (range) | 16 (0–59) | 15 (0–85) | 11 (0–30) | 0.19 |
| PLT units, day 31–90 *, median (range) | 8 (1–98) | 6 (1–300) | 4 (1–50) | 0.48 |
* among transfused patients. MRD HLA-matched related donor; MUD HLA-matched unrelated donor; UCBT, umbilical cord blood transplant; CuI, cumulative incidence; CI, confidence interval; RBC, red blood cell; PLT, platelet. Bold font indicates statistical significance